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Will Artificial Intelligence for Drug Discovery 
Impact Clinical Pharmacology?
Alex Zhavoronkov1 , Quentin Vanhaelen1  and Tudor I. Oprea2,3,4,5,6,*
As the field of artificial intelligence and machine learning (AI/ML) for drug discovery is rapidly advancing, we 
address the question “What is the impact of recent AI/ML trends in the area of Clinical Pharmacology?” We address 
difficulties and AI/ML developments for target identification, their use in generative chemistry for small molecule 
drug discovery, and the potential role of AI/ML in clinical trial outcome evaluation. We briefly discuss current trends 
in the use of AI/ML in health care and the impact of AI/ML context of the daily practice of clinical pharmacologists.
The field of artificial intelligence and machine learning (AI/
ML) has witnessed many changes recently, particularly with re-
spect to deep learning (DL) methods (Figure 1; Table 1), enabled 
both by hardware improvements and the availability of very large 
training datasets (“big data”). As biomedical data are becoming 
increasingly more available in ML-ready digital formats, due to 
technological advances, public policy efforts, and community 
engagement, it is now possible to deploy AI/ML techniques to 
support healthcare research and services. This includes, for ex-
ample, risk-based guidance with DL-models used for predicting 
avoidable hospital readmissions, clinical trial participation selec-
tion with optimized patient selection and recruiting techniques, 
often paired with more effective patient monitoring during clini-
cal trials, or medical devices accessing individual patient data and 
informing medical decisions.
This begs the question, what is the potential impact of AI/ML 
developments in the area of clinical pharmacology? In its broadest 
terms, clinical pharmacology can be defined1 as “all aspects of the 
study and use of drugs in humans,” and covers a wide range of dis-
ciplines, from molecular pharmacology and the way drugs act at 
the molecular level, to epidemiology and related disciplines at the 
population level. Here, we briefly discuss specific AI/ML trends in 
target identification and small molecule drug discovery and their 
potential impact for clinical pharmacologists in the next decade.
AI/ML IN TARGET DISCOVERY
To date, the choice of novel biomolecular drug targets in pharma-
ceutical research and development (i.e., target selection or target 
prioritization) remains an uncertain process. Although the major-
ity of therapeutics are associated with, and act via protein targets, 
novel mechanistic target classes and procedures could be success-
fully exploited to cure disease (Figure 2). In a broad definition, 
“drug targets” are material entities with a quantifiable mass, typi-
cally macromolecules that physically interact with the therapeutic 
agent. Whereas drug targets are characteristically native to the 
biological system on which the drug acts (“native” can also imply a 
disease state such as mutated or fused genes/proteins), a variety of 
drug targets are also not native (e.g., microbial infections or para-
sitic infestations). Furthermore, the physical interaction between 
therapeutic agents and the intended targets causes detectable ef-
fects in living systems, although the clinical outcomes may be due 
to downstream effects.
Against this backdrop, it is important to accurately map the 
interactions between approved drugs and their efficacy targets 
(i.e., the targets through which medicines exert their therapeu-
tic effect).2 Currently, 11% of the human proteome is annotated 
with small molecule probes, whereas one in three proteins re-
mains understudied (i.e., their function and role in human bi-
ology and disease is not understood).3 The fact that in-depth 
biological insights are limited to a small number of proteins4 
is (for the most part) due to a causality dilemma: The study of 
specific genes and proteins requires specific biomolecular tools 
(e.g., antibodies, chemical probes, etc.). For understudied genes, 
the availability of specific tools is unlikely. The lack of such tools 
perpetuates the lack of interest in exploring the dark corners of 
the genome.
With target prioritization in mind, there is an increasing trend 
to apply network (topological) methods, such as knowledge graphs 
(Table 1), to impute novel protein-phenotype or protein-func-
tion associations by seeking different network paths that connect 
proteins/genes to specific properties.3 One such methodology, 
MetaPath,5 can be used to prioritize novel drug targets. These AI/
ML techniques are well suited for big data (e.g., -omics datasets, 
phenotypic and expression data, disease associations, etc.). Such 
methods can identify combinations of genetic variants or abnor-
malities that cause disease, including cases where causal genes are 
known or unknown.6 Indeed, progress in data integration com-
bined with novel AI/ML algorithms and disease causality model-
ing7 will likely shift the paradigm and establish unbiased ways for 
target selection and prioritization.
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Figure 1 (a) A deep neural network (DNN) is a collection of neurons organized in a sequence of multiple layers. There are three types of 
layers. The input layer (L1), which contains the features extracted from the input data. Second, there are the hidden layers (L2, L3, and L4). 
Each of them is a set of nodes acting as computational units. The neurons implement a nonlinear mapping from the input to the output. This 
mapping is learned from the data by adapting the weights of each neuron. The output layer (L5) is similar to the hidden layer but produces 
the final output. The number of nodes in the output layer depends on the type of task to be solved. (b) Traditional machine learning (ML) 
relies on feature engineering, which transforms raw data into features that better represent the predictive task. DNNs discover the mapping 
from representation to output and learn the most informative features from data. This ability to automatically extract high-dimensional 
abstract information from a data without the need to hand-design features and the flexibility and adaptability of the model architecture are 
two advantages of DNN in the context of molecular design. (c) Depending on the balance between the levels of experimental and theoretical 
modeling, the outputs of ML methods can be difficult for humans to interpret (Table 1). For standard ML, the features are interpretable and the 
role of the algorithm is to map the representation to output. An interpretation for a decision made can be retrieved by scrutinizing the inference 
process. For deep learning methods, although the input domain of the DNN is also interpretable, the learned internal representations and the 
flow of information through the network are harder to analyze and modules must be implemented to interpret the output.
Table 1 A summary of common terms in machine learning
Machine learning (ML): ML refers to algorithms that learn from and make predictions on data by building a model from sample inputs. ML is 
used for computing tasks where designing and programming explicit algorithms with good performance is difficult or infeasible. Today, most 
common traditional ML methods are k-nearest neighbors (kNNs), logistic regression (LR), support vector machines (SVMs), gradient boosting 
machines (GBMs), and random forest (RF). The performance of ML methods can vary depending on the type of task (regression or classifica-
tion), types, and amount of data to handle.
Deep learning (DL): DL refers to a class of ML techniques that exploit many layers of nonlinear computational units to model complex rela-
tionships among data. These architectures, composed of multiple layers, are commonly called deep neural networks (DNNs), or sometimes 
stacked neural networks. The difference between the single-hidden-layer artificial neural networks (ANNs) and DNNs is the depth; that is, 
the number of layers of nodes through which data are processed. Usually, more than three layers (including input and output) qualify as 
“deep” learning. Thus, “deep” is a technical term that means more than one hidden layer. DNNs use a cascade of many layers of nonlinear 
processing units for feature extraction. Each successive layer uses the output from the previous layer as input. Higher level features are de-
rived from lower level features to form a hierarchical representation. This hierarchy of features is called a deep architecture. These methods 
are capable of learning multiple levels of representations that correspond to different levels of abstraction. These levels form a hierarchy of 
concepts.
Generative Adversarial Networks (GANs): GANs are structured, probabilistic models for generating data. Being an unsupervised technique, 
GANs can be used to generate data similar to the dataset that the GAN was trained on. A GAN consists of two DNNs called Discriminator 
and Generator. The discriminator estimates the probability that a given sample is coming from the real dataset. It works as a critic and is 
optimized to distinguish the fake samples from the real ones. The generator outputs synthetic samples using a noise variable as input fol-
lowing a distribution. It is trained to capture the real data distribution so that it can generate samples with distribution, which are as real as 
possible. The generator should improve its output until the discriminator is unable to distinguish the generated output from the real ones. 
The two models compete against each other during the training process. The goal of the generator is to try to trick the discriminator while 
the discriminator attempts to not be cheated. This process happening between the two models motivates them to improve their functionali-
ties in order to obtain generated samples indistinguishable from the real data.
Reinforcement learning (RL): RL refers to goal-oriented algorithms, which learn how to attain a complex objective or maximize along a par-
ticular dimension over many steps. RL algorithms operate in a delayed return environment, where it is not straightforward to figure out which 
action leads to which outcome over many time steps. Thus, RL aims at correlating immediate actions with the delayed returns they produce. 
The reinforcement takes place in the sense that RL algorithms are penalized when making the wrong decisions, and they get rewarded when 
making the right one. RL algorithms are expected to increase performance in more ambiguous, real-life environments.
Interpretability: Understanding the output of a model in terms of its inputs and intrinsic properties. Interpretability is the idea that humans 
should understand, at some level, the decisions being made by algorithms. Interpretability is useful to understand whether a model is work-
ing properly and how the model could be modified to be improved.
Knowledge graphs: A knowledge graph is a database that stores information in a graphical format and can be used to generate a graphi-
cal representation of the relationships between any of its data points. The advantage over the older, relational style database is that the 
relationships between any data points can be calculated far more quickly and with less compute power overheads, regardless of whether the 
data points fit neatly together into a table.
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AI/ML FOR CLINICAL TRIAL OUTCOME PREDICTION AND 
DESIGN
The failure rate of clinical trials contributes to the inefficiency 
of the drug development cycle: Clinical trials can take up to 
7–10  years, with costs of $1.46 billion of $2.56 billion in capi-
talized costs for bringing a new drug to market. Each failed trial 
impairs not only the investment into the trial itself but also pre-
clinical development costs, rendering the loss per failed clinical 
trial at $800 million to $1.4 billion. Inefficient patient selection 
and recruiting, combined with the inability to effectively monitor 
patients during trials, are two of the main causes for high failure 
rates. AI/ML technologies have begun to be deployed within key 
steps of clinical trial design from study preparation to execution, 
leading to trial success rate improvement.8
For instance, IBM Watson has developed a system for Clinical 
Trial Matching, which uses the large quantity of structured and 
unstructured patient electronic medical record data and the abun-
dance of available trials to create detailed profiles of clinical find-
ings for the patients to compare to trial eligibility criteria. As the 
system incorporates all the complex protocol criteria to consider, it 
eliminates the need to manually sort through and analyze complex 
enrollment criteria and enables clinicians to optimize their search 
for clinical trials for an eligible patient or for finding patients eligi-
ble for a given trial. Those two tasks are otherwise challenging and 
time-consuming. The improvement in screening efficiency and 
more effective patient recruitment help increase clinical trial en-
rollment targets. This system can also be useful to help manage and 
track patients through the recruitment process and share progress 
across networks in near real-time.
Clinical trials outcome prediction via AI/ML models could 
further reduce the cost of clinical trials by improving success rate. 
The purpose of such models is to predict the likelihood of success 
by analyzing compound responses, side effects, etc. For instance, 
a DL-based model was used to predict the outcomes of phase I/
II clinical trials.9 This pipeline predicted the drug-induced path-
way activation and related side effects. Side effect probabilities and 
pathway activation scores were used to train a model to predict 
clinical trial outcomes. Separate models were used to predict bio-
availability and target-related properties, such as tissue selectivity, 
and chemical features combined with target-based features to pre-
dict clinical drug toxicity.10 We anticipate that improved AI/ML 
models could be used for clinical trials outcome prediction.
Other projects, such as the Virtual Physiological Human, aim to 
develop in silico approaches to support in silico clinical trials.11 The 
development of such AI/ML frameworks can be used to synthesize 
the physiological and pathological information about a patient at 
different scales of space and time, with the ultimate aim of pro-
ducing patient-specific and subpopulation-specific predictions for 
diagnosis, prognosis, posology, and treatment planning.
GENERATIVE CHEMISTRY: AI/ML FOR SMALL MOLECULE 
DRUG DISCOVERY
One of the first applications of AI/ML in the context of early 
drug discovery was the quantification of “druglikeness,” which 
attempts to mimic the intuition of medicinal chemists in estimat-
ing the likelihood that novel chemical structures are more likely 
to become “drugs.” Although “drug (in the regulatory sense) is 
not an intrinsic property of chemicals,”12 the process of estimat-
ing druglikeness using AI/ML remains a practical chemical space 
navigation tool, as the number of possible drug-like chemicals 
can exceed 1023. Regardless of algorithms, such methods do not 
predict “drug” as an attribute, but rather score a multiparametric 
similarity, interpreted as “these molecules are similar to other mol-
ecules that chemists consider to be of pharmaceutical interest.” 
The lack of true negative data has hindered a more rigorous ap-
proach in this direction, because > 40% of “non-drugs” do contain 
druglike fragments,13 due to the fact that chemical vendors adapt 
their own AI/ML druglikeness models to boost sales to pharma-
ceutical companies. Which raises the question, can AI/ML sug-
gest what compounds to make next? Considering the encouraging 
results obtained with Generative Adversarial Networks (GANs)14 
combined with reinforcement learning (RL)15 (Table 1) and other 
architectures, such as variational auto-encoder, AI/ML has gained 
credibility as an alternative to standard drug discovery tools.
Indeed, GAN/RL methods have successfully been applied to 
design generate molecules in silico, given a desired set of chemical 
properties. From the first DL-based molecular generator using 
an adversarial auto-encoder to generate molecular fingerprints,16 
significant progress was made in several areas: First, molecular 
representation. Beginning with the Wisswesser line notation, 
several ways to encode molecular structures are available, such as 
chemical fingerprints,17 Simplified Molecular Input Line System 
(SMILES),18 and molecular graphs.19 Thus, GAN methods using 
fingerprints,16 SMILES,20 chemical graphs, and 3D wave-trans-
forms21 have been proposed, with different strengths concerning 
the amount and type of structural information and features kept or 
lost during encoding. Second, molecular property profiles: GAN 
architectures need to generate not just valid chemical structures, 
but also molecules matching certain bioactivity, novelty, diversity 
Figure 2 Therapeutic target categories. Although sugars and, to a 
great extent, lipids are not currently targeted by approved drugs, they 
are the subject to drug discovery research.
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Figure 3 A Generative Adversarial Network–reinforcement learning (RL) model is made of three main components. (1) The generator captures 
the real-data and generates synthetic samples as real as possible. (2) The discriminator estimates the probability that a sample is coming 
from the real dataset. The generator should improve its output until the discriminator is unable to distinguish the generated from the real ones 
and the discriminator is optimized to distinguish the synthetic samples from the real ones. (3) The RL module rewards the discriminator based 
on how accurate it is in distinguishing the synthetic samples from the real ones. The RL optimization procedure drives the hidden space, a 
multimodal distribution of compressed molecular structures used for the generation of novel compounds, toward the desired objective of 
generating novel molecules with specific properties.
Figure 4 Timeline summarizing the key advances in designing molecular generator models. The creation of the Generative Adversarial Network 
(GAN) architecture was a turning point as this enabled to build architectures with unprecedented generative capabilities. SMILES, Simplified 
Molecular Input Line System; VAE, variational auto-encoder.
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profiles, and, preferably, other features. These constraints led to the 
emergence of generative models, which eventually were combined 
with RL (Figure 3). Various architectures have been designed so 
far (Figure 4). These methods ensure that the generated molecules 
have suitable chemical properties using filters, reward functions, 
and evaluation metrics run in parallel with model architectures. 
Despite the increasing number of models, architectures, data types, 
and learning methods, it is difficult to assess model performance 
without a “gold standard” benchmark and evaluation metrics. 
Molecular Sets (MOSES) is one such platform22 that offers ways 
to evaluate and compare generative model performance.
An important milestone for the use of generative chemistry in 
drug discovery was recently accomplished, demonstrating that 
generated molecules can be synthesized, are active in vitro, met-
abolically stable, and show in vivo activity in disease-relevant 
models. The first example of an in vitro active molecule gener-
ated using the conditional adversarial autoencoder GAN was the 
JAK3 inhibitor.23 Another generative model, Generative Tensorial 
Reinforcement Learning (GENTRL) produced in vivo active 
DDR1 and DDR2 inhibitors.24 Here, DDR1 and DDR2 inhib-
itors with different property and selectivity profiles were assayed 
in vitro, followed by in vivo mouse experiments that validate the 
pharmacokinetics of DDR1 inhibitor. To date, the design/make/
test/evaluate feedback loop in drug discovery can afford a limited 
number of cycles because each step is resource and time-consum-
ing. Given these promising in vitro and in vivo results derived from 
generative reinforcement learning technologies, AI/ML methods 
are poised to become an integral part of the drug design cycle. 
However, the time it takes to validate the molecules produced by 
generative and other ML systems by far exceeds the time it takes 
to build and train the models. In addition, while multiple groups 
worldwide are working on the automated synthesis and in vitro 
validation machinery, synthesis and experimental validation will 
remain the main gating factor for the transformation of drug dis-
covery using AI/ML over the next few years.
AI/ML IN CLINICAL PHARMACOLOGY: CHALLENGES AND 
OUTLOOK
Currently, the key challenges in drug discovery are related to 
chemical structures (e.g., toxicity, side effects, or even intellectual 
property), choosing the right drug target or the appropriate dos-
age for a specific patient subpopulation. Despite major advances 
in clinical pharmacology, the silo-ing of late preclinical and clin-
ical data remains a critical issue blocking the deployment of AI/
ML technologies. The pharmaceutical industry does not typically 
share pharmacokinetic and pharmacodynamic measurements for 
most of the candidate drugs or their combinations, unless the 
drugs are approved for human use. Indeed, unlike other areas of 
research and development, only a small fraction of the drug dis-
covery data overall is available for training AI/ML models. This 
is particularly with respect to true negative data. The problem 
pervades not only for, for example, discriminating “drugs” from 
“nondrugs,” but also with respect to AI/ML models for novel tar-
get-disease associations, for understanding why clinical trials were 
discontinued, why drugs were withdrawn, or even accessing com-
plete datasets from successful clinical trials. Nonetheless, there is 
no doubt that clinical development is currently moving through 
major transformation and that the usage of AI/ML is accelerating.
On a daily basis, “a clinical pharmacologist is a medically qual-
ified practitioner who teaches, does research, frames policy, and 
gives information and advice about the actions and proper uses of 
medicines in humans, and implements that knowledge in clinical 
practice.”1 We can safely state that recent AI/ML developments 
are likely to impact clinical pharmacologists at all levels in the next 
decade:
• In teaching, the use of data-intensive methodologies for exam-
ple, literature searching and processing, as well as interactions 
with on-line predictive AI/ML models, are likely to increase. 
All-encompassing resources, such as ADMETLab, http://
admet.scbdd.com/#, or specific resources, such as software for 
drug-drug interactions25 are likely to benefit and co-evolve with 
increased usage of AI/ML methods.
• In research, the use of AI/ML methods is accelerating pace, as 
detailed above.
• In framing policy, AI/ML methods are anticipated to influence 
healthcare in most countries.
• For the proper use of medicines, most “digital natives” (i.e., 
patients and scientists who started to use computers/tablets/
smartphones from an early age) are seeking healthcare and 
drug information via social media and web-based platforms. 
Predictive analytics (e.g., anticipating query terms and per-
sonalized searches) for drug-related information are already 
available. Advanced AI/ML systems, tailored to an individual’s 
medical and genomic history are around the corner.
One of the major challenges of the pharmaceutical industry is 
the many areas of drug discovery and development can take years, 
cost hundreds of millions of dollars, and are often disconnected 
from the planning perspective and managed by different people. 
The time it takes to identify a disease target and formulate a biolog-
ical hypothesis may take decades and cost billions. The typical time 
from identifying a hit molecule for a given target to a marketed 
product usually takes 12.5 years. In addition, although the amount 
of clinical pharmacology data is rapidly increasing, it is likely to 
be substantially less abundant than the amount of experimental 
chemistry and in vitro high-throughput screening data. There are 
very few studies with measuring a large number of parameters in 
vitro, in mice and in humans with published freely available data. 
The majority of these studies was conducted by the pharmaceutical 
companies that rightfully treat these data as a competitive advan-
tage making clinical pharmacology more difficult for the advances 
in AI/ML to disrupt.
The next decade may witness seamless integration between 
human (“natural”) intelligence and AI systems. Intelligent per-
sonal assistants (e.g., Siri, Alexa, etc.) already offer support with re-
spect to navigation, entertainment, and shopping. Medical advice, 
specifically regarding the use of medicines, is quite likely on the “to 
do” list for most developers competing in this sector. It remains to 
be seen which one (if any) will be endorsed by professional asso-
ciations, such as American Society for Clinical Pharmacology and 
Therapeutics (ASCPT; https://www.ascpt.org/) on the basis of 
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accuracy and precision. Although most AI/ML developments are 
expected to benefit patients and scientists alike, we do anticipate 
that these trends will not replace clinical pharmacologists in the 
next decade, and clinical pharmacology in general will be disrupted 
slower than the other fields of drug discovery and development. 
There is, however, a strong incentive for clinical pharmacologists 
to adapt, to monitor such trends, and to become cognizant on the 
usage and perils of AI/ML systems, particularly for those that in-
fluence their daily practice. There needs to be a community and 
regulatory effort for open data sharing to make larger number of 
preclinical and clinical pharmacology data available for the ML 
community to use in order to accelerate the AI/ML progress in the 
area. Note: The GENTRL-generated molecule is similar to pona-
tinib. Following the publication of the GENTRL results, guide-
lines for assessing AI-generated molecules have been proposed by 
Walters and Murcko.26
FUNDING
Part of this work was supported by the National Institutes of Health 
(NIH) grants P30 CA118100, U24 CA224370, U01 CA239108, and U24 
TR002278 (T.I.O.).
CONFLICT OF INTEREST
A.Z. and Q.V. are affiliated with Insilico Medicine Inc., a company 
developing an AI-based end-to-end integrated pipeline for drug discovery 
and development and engaged in aging and cancer research. T.I.O. is 
a former full-time employee of AstraZeneca (1996–2002) and has 
received honoraria, or consulted for, Abbott, AstraZeneca, Chiron, 
Genentech, Infinity Pharmaceuticals, Merz Pharmaceuticals, Merck 
Darmstadt, Mitsubishi Tanabe, Novartis, Ono Pharmaceuticals, Pfizer, 
Roche, Sanofi, and Wyeth. His spouse was a full-time employee of 
AstraZeneca (2002–2014) and is a full-time employee of Genentech Inc.
© 2020 The Authors. Clinical Pharmacology & Therapeutics 
published by Wiley Periodicals, Inc. on behalf of American Society for 
Clinical Pharmacology and Therapeutics.
This is an open access article under the terms of the Creative Commons 
Attribution-NonCommercial License, which permits use, distribution and 
reproduction in any medium, provided the original work is properly cited 
and is not used for commercial purposes.
 1. Aronson, J.K. A manifesto for clinical pharmacology from 
principles to practice. Br. J. Clin. Pharmacol. 70, 3–13 (2010).
 2. Santos, R. et al. A comprehensive map of molecular drug targets. 
Nat. Rev. Drug Discov. 16, 19–34 (2017).
 3. Oprea, T.I. et al. Unexplored therapeutic opportunities in the 
human genome. Nat. Rev. Drug Discov. 17, 317–332 (2018).
 4. Edwards, A.M. et al. Too many roads not taken. Nature 470, 
163–165 (2011).
 5. Sun, Y., Barber, R., Gupta, M., Aggarwal, C.C. & Han, J. Co-author 
relationship prediction in heterogeneous bibliographic networks. 
International Conference on Advances in Social Networks Analysis 
and Mining, Kaohsiung, Taiwan, July 25, 2011–July 27, 2011. 
 6. Papadimitriou, S. et al. Predicting disease-causing variant 
combinations. Proc. Natl. Acad. Sci. USA 116, 11878–11887 
(2019).
 7. Bang, S., Kim, J.-H. & Shin, H. Causality modeling for directed 
disease network. Bioinformatics 32, i437–i444 (2016).
 8. Harrer, S., Shah, P., Antony, B. & Hu, J. Artificial intelligence 
for clinical trial design. Trends Pharmacol. Sci. 40, 577–591 
(2019).
 9. Artemov, A.V., Putin, E., Vanhaelen, Q., Aliper, A., Ozerov, I.V., 
& Zhavoronkov, A. Integrated deep learned transcriptomic and 
structure-based predictor of clinical trials outcomes. bioRxiv 
(2016). https://doi.org/10.1101/095653
 10. Gayvert, K.M., Madhukar, N.S. & Elemento, O. A data-driven 
approach to predicting successes and failures of clinical trials. 
Cell Chem. Biol. 23, 1294–1301 (2016).
 11. Viceconti, M., Henney, A. & Morley-Fletcher, E. In silico clinical 
trials: how computer simulation will transform the biomedical 
industry. Int. J. Clin. Trials 3, 37 (2016).
 12. Ursu, O., Rayan, A., Goldblum, A. & Oprea, T.I. Understanding 
drug-likeness. WIREs Comput. Mol. Sci. 1, 760–781 (2011).
 13. Ursu, O. & Oprea, T.I. Model-free drug-likeness from fragments. J. 
Chem. Inf. Model. 50, 1387–1394 (2010).
 14. Goodfellow, J. et al. Generative adversarial nets. Adv. Neural Inf. 
Process. Syst. 27, 2672–2680 (2014).
 15. Kulkarni, P. Reverse Hypothesis Machine Learning. (Springer, 
Cham, Switzerland, 2017).
 16. Kadurin, A. et al. The cornucopia of meaningful leads: applying 
deep adversarial autoencoders for new molecule development in 
oncology. Oncotarget 8, 10883–10890 (2017).
 17. Durant, J.L., Leland, B.A., Henry, D.R. & Nourse, J.G. 
Reoptimization of MDL keys for use in drug discovery. J. Chem. Inf. 
Comput. Sci. 42, 1273–1280 (2002).
 18. Weininger, D. SMILES, a chemical language and information 
system. 1. Introduction to methodology and encoding rules. J. 
Chem. Inf. Comput. Sci. 28, 31–36 (1988).
 19. Akutsu, T. & Nagamochi, H. Comparison and enumeration of chemical 
graphs. Comput. Struct. Biotechnol. J. 5, e201302004 (2013).
 20. Putin, E. et al. Adversarial threshold neural computer for 
molecular de novo design. Mol. Pharm. 15, 4386–4397 (2018).
 21. Kuzminykh, D. et al. 3D Molecular representations based on the 
wave transform for convolutional neural networks. Mol. Pharm. 
15, 4378–4385 (2018).
 22. Polykovskiy, D.et al.Molecular sets (MOSES): a benchmarking 
platform for molecular generation models. arXiv [cs.LG] (2018) 
<http://arxiv.org/abs/1811.12823>.
 23. Polykovskiy, D. et al. Entangled conditional adversarial 
autoencoder for de novo drug discovery. Mol. Pharm. 15, 4398–
4405 (2018).
 24. Zhavoronkov, A. et al. Deep learning enables rapid identification 
of potent DDR1 kinase inhibitors. Nat. Biotechnol. 37, 1038–1040 
(2019).
 25. Kheshti, R., Aalipour, M. & Namazi, S. A comparison of five 
common drug-drug interaction software programs regarding 
accuracy and comprehensiveness. Am. J. Pharmacogenomics 5, 
257–263 (2016).
 26. Walters, W.P. & Murcko, M. Assessing the impact of generative AI 
on medicinal chemistry. Nat. Biotechnol. 38, 143–145 (2020).
REVIEW
